An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Completed · Phase 1/Phase 2

Conditions studied: Neoplasms by Site

In brief

The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. The following tumor types are included in this study: Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously been treated with immunotherapy.

Key facts

Study ID

NCT01968109

Run by

Bristol-Myers Squibb

People needed

1482

Starts

2013-11-05

Expected to finish

2025-02-03

Last updated by the study team

2026-04-06

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• For Dose escalation: subjects with cervical, ovarian, bladder and colorectal cancer (CRC), head and neck, gastric and hepatocellular cancer naive to immuno-oncology agents; 1st line melanoma and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to IO; NSCLC progressing while on or after therapy with anti-PD1/anti-PDL-1 and melanoma subjects progressed while-on or after treatment with anti-PD1 or anti-PDL1 with or without anti-CTLA-4.
• For Dose Expansion: all of the above in escalation except for cervical, ovarian, and CRC
• Progressed, or been intolerant to, at least one standard treatment regimen, except for participants in 1st line cohorts.
• ECOG performance status between 0 and 2
• At least 1 lesion with measurable disease at baseline
• Availability of an existing tumor biopsy sample (and consent to allow pre-treatment tumor biopsy)

You may not qualify if…

• Primary central nervous system (CNS) tumors or solid tumors with CNS metastases as the only site of active disease
• Autoimmune disease
• Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent
• Uncontrolled CNS metastases
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• Local Institution - 0053 — Aurora, Colorado, United States
• Local Institution - 0058 — Tampa, Florida, United States
• Local Institution - 0003 — Chicago, Illinois, United States
• Local Institution - 0048 — Niles, Illinois, United States
• Local Institution - 0004 — Baltimore, Maryland, United States
• Local Institution - 0001 — Boston, Massachusetts, United States
• Local Institution - 0011 — Detroit, Michigan, United States
• Local Institution - 0051 — Rochester, Minnesota, United States
• Local Institution - 0044 — St Louis, Missouri, United States
• Local Institution - 0005 — New York, New York, United States
• Local Institution - 0002 — Portland, Oregon, United States
• Local Institution - 0047 — Allentown, Pennsylvania, United States
• Local Institution - 0010 — Pittsburgh, Pennsylvania, United States
• Local Institution - 0057 — Dallas, Texas, United States
• Local Institution - 0045 — Houston, Texas, United States
• Local Institution - 0008 — Seattle, Washington, United States
• Local Institution - 0029 — North Sydney, New South Wales, Australia
• Local Institution - 0031 — Brisbane, Queensland, Australia
• Local Institution - 0039 — Southport, Queensland, Australia
• Local Institution - 0033 — Melbourne, Victoria, Australia
• Local Institution - 0032 — Nedlands, Western Australia, Australia
• Local Institution - 0023 — Vienna, Austria
• Local Institution - 0024 — Vienna, Austria
• Local Institution - 0049 — Toronto, Ontario, Canada
• Local Institution - 0043 — La Jolla, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.